Levodopa-induced postural hypotension. Treatment with fludrocortisone.
Six parkinsonian patients with symptomatic postural hypotension secondary to levodopa therapy were treated with 0.05 to 0.2 mg of fludrocortisone acetate daily for six to ten months. Severe orthostatic light-headedness and frequent syncope had previously been alleviated only be reducing the dosage of levodopa to levels producing less than optimal antiparkinsonian benefits. In all six patients, symptoms were alleviated satisfactorily, and supine and upright blood pressures returned to normal levels during treatment with fludrocortisone acetate. There were no adverse reactions. Fludrocortisone acetate is an effective and safe drug for the treatment of severe and otherwise intractable postural hypotension secondary to therapy with levodopa.
D000368:Aged; D001794:Blood Pressure / Q000187:drug effects; D005260:Female; D005438:Fludrocortisone / Q000627:therapeutic use*; D006801:Humans; D007024:Hypotension, Orthostatic / Q000139:chemically induced* / Q000188:drug therapy; D007668:Kidney / Q000187:drug effects; D007980:Levodopa / Q000009:adverse effects* / Q000627:therapeutic use; D009318:Natriuresis / Q000187:drug effects; D010300:Parkinson Disease / Q000188:drug therapy; D011311:Pressoreceptors / Q000187:drug effects; D011941:Receptors, Adrenergic
D011941:Receptors, Adrenergic; D007980:Levodopa; D005438:Fludrocortisone